首页> 外文期刊>Respiration: International Review of Thoracic Diseases >Treatment of invasive pulmonary aspergillosis in neutropenic patients by additional bronchoscopic amphotericin B instillation.
【24h】

Treatment of invasive pulmonary aspergillosis in neutropenic patients by additional bronchoscopic amphotericin B instillation.

机译:通过额外的支气管镜两性霉素B滴注治疗中性粒细胞减少症患者的侵袭性肺曲霉病。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Invasive pulmonary aspergillosis (IPA) remains a life-threatening condition despite systemic antifungal therapy. OBJECTIVES: This retrospective analysis investigated whether additional bronchoscopic instillation of amphotericin B (amB) would improve efficacy of antifungal treatment in patients with haematological malignancies suffering from IPA. METHODS: Twenty patients (40.6 +/- 14.2 years, 14 male) with preceding chemotherapy, bone marrow or stem cell transplantation complicated by severe IPA who did not respond sufficiently to systemic antifungal therapy were additionally treated by repeated bronchoscopic instillations of amB solution (91 instillations, on average 4.6 +/- 2.2 instillations per patient over a period of 24.1 +/- 21.0 days). Therapeutic response to this combined treatment regimen was monitored by chest X-ray and CT scan. RESULTS: The mean infiltration sizes during systemic antifungal therapy alone (mean duration 11.9 +/- 9.9 days) did not change significantly. However, after additional bronchoscopic instillation of amB solution infiltration sizes were reduced significantly (p < 0.05). A total resolution of infiltrates was seen in 3 and a partial reduction in 13 of 20 patients. Mean duration of total antifungal treatment was 50.1 +/- 24.0 days. The mean follow-up period was 34.1 +/- 31.2 months. The IPA-related mortality rate was 18.8% (3 of 16 patients). CONCLUSIONS: Additional bronchoscopic instillation of amB may improve the efficacy of systemic antifungal therapy in patients with haematological malignancies complicated by severe IPA. Bronchoscopic instillation of amB should be considered as an additional treatment option in cases with IPA unresponsive to systemic therapy.
机译:背景:尽管进行了全身性抗真菌治疗,但侵袭性肺曲霉病(IPA)仍然危及生命。目的:这项回顾性分析调查了在支气管镜下补充两性霉素B(amB)是否会改善患有IPA的血液系统恶性肿瘤患者的抗真菌治疗效果。方法:对20例先前化疗,骨髓或干细胞移植并发严重IPA并没有对全身抗真菌治疗充分反应的患者(40.6 +/- 14.2岁,男14例)再次通过支气管镜滴注amB溶液进行治疗(91滴注,平均每位患者在24.1 +/- 21.0天的时间内滴注4.6 +/- 2.2次)。通过胸部X线和CT扫描监测对该联合治疗方案的治疗反应。结果:仅全身性抗真菌治疗期间的平均浸润大小(平均持续时间11.9 +/- 9.9天)没有显着变化。但是,在再次用支气管镜滴加amB溶液后,浸润大小明显减少(p <0.05)。 20例患者中有3例总浸润消失,13例部分减少。总体抗真菌治疗的平均持续时间为50.1 +/- 24.0天。平均随访期为34.1 +/- 31.2个月。与IPA相关的死亡率为18.8%(16例患者中的3例)。结论:对于患有血液系统恶性肿瘤并发严重IPA的患者,额外的支气管镜滴注amB可能会提高全身抗真菌治疗的疗效。如果IPA对全身治疗无反应,则应考虑将支气管镜滴注amB作为另一种治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号